Christina Bonner
Chicago, ILNPI 1043238231
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 282 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 35 manufacturers reported payments, led by AbbVie at 27.8% of the total.
Across 282 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Organon$419
- Coopersurgical, Inc.$382
- Mayne Pharma Commercial LLC$344
- Hologic Sales And Service, LLC$241
- Bayer$220
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,38698%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,533 |
| Organon | 27 | $419 |
| Coopersurgical, Inc. | 19 | $382 |
| Mayne Pharma Commercial LLC | 17 | $344 |
| Hologic Sales And Service, LLC | 15 | $241 |
| Bayer | 9 | $220 |
| Pfizer | 8 | $207 |
| Avion Pharmaceuticals | 12 | $203 |
| Mylan Pharmaceuticals Inc. | 8 | $191 |
| Agile Therapeutics, Inc. | 9 | $190 |
| Merck | 10 | $180 |
| Exeltis, USA Inc. | 8 | $157 |
| Myovant Sciences Inc. | 6 | $125 |
| Astellas Pharma US Inc | 5 | $122 |
| AMAG Pharmaceuticals, Inc. | 6 | $107 |
| Millicent US Inc | 6 | $97 |
| Biogen | 4 | $86 |
| Channel Medsystems, Inc. | 1 | $79 |
| Novo Nordisk | 3 | $65 |
| Seqirus USA Inc | 3 | $63 |
| Exact Sciences | 3 | $61 |
| BD | 2 | $59 |
| Therapeuticsmd, Inc. | 3 | $57 |
| Gynesonics, Inc. | 2 | $38 |
| Dysis Medical, Inc. | 2 | $37 |
| Amgen | 2 | $37 |
| Vertical Pharmaceuticals, LLC | 2 | $36 |
| Lupin Inc. | 2 | $32 |
| Boston Scientific | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Mission Pharmacal Company | 2 | $25 |
| Scynexis, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Monaghan Medical Corporation | 1 | $17 |
| Duchesnay USA Incorporated | 1 | $13 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 17 | $1,627 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.